Anthracycline-induced cardiotoxicity: A review of pathophysiology, diagnosis, and treatment

Current Treatment Options in Cardiovascular Medicine

Volumn 16, Issue 6, 2014, Pages

  Raj, Shashi ^a,b   Franco, Vivian I ^a   Lipshultz, Steven E ^a,b,c,d  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c UNIVERSITY OF MIAMI   (United States)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anthracycline; Cardiomyopathy; Childhood cancer survivor; Dexrazoxane; Left ventricular dysfunction

Indexed keywords

ANTHRACYCLINE; DOXORUBICIN; RAZOXANE;

ANTHRACYCLINE INDUCED CARDIOTOXICITY; CARDIOTOXICITY; CARDIOVASCULAR RISK; DRUG EFFICACY; GENE MUTATION; GROWTH HORMONE DEFICIENCY; HEART PROTECTION; HEMOCHROMATOSIS; HUMAN; HYPERTENSION; PATHOPHYSIOLOGY; QUALITY OF LIFE; REVIEW;

EID: 84901262265     PISSN: 10928464     EISSN: 15343189     Source Type: Journal    
DOI: 10.1007/s11936-014-0315-4     Document Type: Review

References (75)

1. American Cancer Society. Cancer Facts and Figures 2013. Atlanta: American Cancer Society; 2013. Available at: http://www.cancer.org/acs/groups/content/ @epidemiologysurveilance/documents/document/acspc-036845.pdf. Accessed 24 Oct 2013.
2. Howlader N,NooneAM, KrapchoM, et al. SEER Cancer Statistics Review, 1975-2010, National Cancer Institute. Bethesda,MD. Available at: http://seer.cancer.gov/csr/1975-2010/. Accessed 24 Oct 2013.
3. Lipshultz SE, Adams MJ, Colan SD, on behalf of the American Heart Association Congenital Heart Defects Committee of the Council on Cardiovascular Disease in the Young, Council on Basic Cardiovascular Sciences, Council on Cardiovascular and Stroke Nursing, Council on Cardiovascular Radiology and Intervention, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Council on Nutrition, Physical Activity and Metabolism, et al. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation. 2013;128:1927-95.
4. Lipshultz SE, Alvarez JA, Scully RE. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart. 2008;94:525-33. (Pubitemid 351441417)
5. Mulrooney DA, Yeazel MW, Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ. 2009;339:b4606.
6. Pein F, Sakiroglu O, Dahan M, et al. Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy. Br J Cancer. 2004;91:37-44. (Pubitemid 39013042)
7. van Dalen EC, van der Pal HJ, Kok WE, Caron HN, Kremer LC. Clinical heart failure in a cohort of children treated with anthracyclines: a long-term followup study. Eur J Cancer. 2006;42:3191-8. (Pubitemid 44872945)
8. Sorensen K, Levitt G, Bull C, Chessells J, Sullivan I. Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival versus late cardiotoxicity. J Clin Oncol. 1997;15:61-8. (Pubitemid 27020558)
9. Lipshultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 1991;324:808-15.
10. Kremer LC, van der Pal HJ, Offringa M, van Dalen EC, VoÛte PA. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann Oncol. 2002;13:819-29. (Pubitemid 34752678)
11. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA. 1991;266:1672-7.
12. Simbre VC, Adams MJ, Deshpande SS, et al. Cardiomyopathy caused by antineoplastic therapies. Curr Treat Options Cardiovasc Med. 2001;3:493-505.
13. Lipshultz SE, Lipsitz SR, Sallan SE, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol. 2005;23:2629-36. (Pubitemid 46179451)
14. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97:2869-79. (Pubitemid 36605157)
15. Krischer JP, Epstein S, Cuthbertson DD, Goorin AM, Epstein ML, Lipshultz SE. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol. 1997;15:1544-52. (Pubitemid 27167391)
16. •• Lipshultz SE, Miller TL, Lipsitz SR, et al. Continuous versus bolus infusion of doxorubicin in children with ALL: long-term cardiac outcomes. Pediatrics. 2012;130:1003-11. This study demonstrates that continuous infusion of doxorubicin offers no cardioprotective advantage over bolus infusion in childhood cancer survivors of high-risk ALL. These findings suggest those pediatric oncologists treating these patients are encouraged to minimize or eliminate the use of continuous anthracycline infusion
17. Huh WW, Jaffe N, Durand JB, Munsell MF, Herzog CE. Comparison of doxorubicin cardiotoxicity in pediatric sarcoma patients when given with dexrazoxane versus as continuous infusion. Pediatr Hematol Oncol. 2010;27:546-57.
18. Barry E, Alvarez JA, Scully RE, et al. Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opin Pharmacother. 2007;8:1039-58. (Pubitemid 46929299)
19. Wouters KA, Kremer LC, Miller TL, Herman EH, Lipshultz SE. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol. 2005;131:561-78. (Pubitemid 43899624)
20. van Dalen EC, Michiels EM, Caron HN, Kremer LC. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev. 2010;3, CD005006.
21. Giantris A, Abdurrahman L, Hinkle A, Asselin B, Lipshultz SE. Anthracycline-induced cardiotoxicity in children and young adults. Crit Rev Oncol Hematol. 1998;27:53-68. (Pubitemid 28275509)
22. Adams MJ, Lipshultz SE. Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: implications for screening and prevention. Pediatr Blood Cancer. 2005;44:600-6. (Pubitemid 40629208)
23. Lipshultz SE, Adams MJ. Cardiotoxicity after childhood cancer: beginning with the end in mind. J Clin Oncol. 2010;28:1276-81.
24. Miller TL, Lipsitz SR, Lopez-Mitnik G, et al. Characteristics and determinants of adiposity in pediatric cancer survivors. Cancer Epidemiol Biomarkers Prev. 2010;19:2013-22.
25. Miller AM, Lopez-Mitnik G, Somarriba G, et al. Exercise capacity in long-term survivors of pediatric cancer: an analysis from the Cardiac Risk Factors in Childhood Cancer Survivors Study. Pediatr Blood Cancer. 2013;60:663-8.
26. •• Lipshultz SE, Lipsitz SR, Kutok JL, et al. Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood highrisk leukemia. Cancer. 2013;119:3555-62. This study demonstrates that doxorubicin-treated survivors of childhood high-risk ALL who were heterozygous for the C282Y allele, one of the most commonly associated mutations in HFE, had a nine-fold increased risk of myocardial injury, compared with noncarriers. Screening for HFE mutations might identify those at higher risk for doxorubicinassociated cardiotoxicity, and inform treatment decisions.
27. van der Pal HJ, van Dalen EC, van Delden E, et al. High risk of symptomatic cardiac events in childhood cancer survivors. J Clin Oncol. 2012;30:1429-37.
28. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin induced congestive heart failure. Ann Intern Med. 1979;91:710-7. (Pubitemid 10218041)
29. Nysom K, Holm K, Lipsitz SR, et al. Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. J Clin Oncol. 1998;16:545-50. (Pubitemid 28135597)
30. Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med. 1995;332:1738-43.
31. Reulen RC, Winter DL, Frobisher C, et al. Long-term cause-specific mortality among survivors of childhood cancer. JAMA. 2010;304:172-9.
32. Levitt G, Anazodo A, Burch M, Bunch K. Cardiac or cardiopulmonary transplantation in childhood cancer survivors: an increasing need? Eur J Cancer. 2009;45:3027-34.
33. Chabner BA, Bertino J, Cleary J, et al. Chemotherapy of neoplastic diseases. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman and Gillman's the pharmacologic basis of therapeutics. 12th ed. New York: McGraw-Hill Medical; 2010. p. 1677-729.
34. Serrano J, Palmeira CM, Kuehl DW, Wallace KB. Cardioselective and cumulative oxidation of mitochondrial DNA following subchronic doxorubicin administration. Biochim Biophys Acta. 1999;1411:201-5. (Pubitemid 29182810)
35. Arola OJ, Saraste A, Pulkki K, et al. Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Res. 2000;60:1789-92. (Pubitemid 30207630)
36. Rebbaa A, Chou PM, Emran M, Mirkin BL. Doxorubicin- induced apoptosis in caspase-8 deficient neuroblastoma cells is mediated through direct action on mitochondria. Cancer Chemother Pharmacol. 2001;48:423-8. (Pubitemid 33139862)
37. Herman EH, Zhang J, Hasinoff BB, Clark Jr JR, Ferrans VJ. Comparison of the structural changes induced by doxorubicin and mitoxantrone in the heart, kidney and intestine and characterization of the Fe (III)-mitoxantrone complex. J Mol Cell Cardiol. 1997;29:2415-30. (Pubitemid 27404434)
38. • Zhang S, Liu X, Bawa-Khalfe T, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012;18:1639-42. This study describes the mediation of Top2b in doxorubicin-induced cardiotoxicity in a mouse model. Cardiomyocyte-specific deletion of Tob2b protected the cardiomyocyte from DNA damage that can lead to defective mitochondria and ROS formation.
39. Kluza J, Marchetti P, Gallego MA, et al. Mitochondrial proliferation during apoptosis induced by anticancer agents: effects of doxorubicin and mitoxantrone on cancer and cardiac cells. Oncogene. 2004;23:7018-30. (Pubitemid 39319164)
40. Bugger H, Guzman C, Zechner C, et al. Uncoupling protein down regulation in doxorubicin-induced heart failure improves mitochondrial coupling but increases reactive oxygen species generation. Cancer Chemother Pharmacol. 2011;67:1381-8.
41. Walder K, Norman RA, Hanson RL, et al. Association between uncoupling protein polymorphisms (UCP2-UCP3) and energy metabolism/obesity in Pima Indians. Hum Mol Genet. 1998;7:1431-5. (Pubitemid 28429924)
42. De Angelis A, Piegari E, Cappetta D, et al. Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function. Circulation. 2010;121:276-92.
43. Kalyanaraman B, Joseph J, Kalivendi S, et al. Doxorubicin- induced apoptosis: implications in cardiotoxicity. Mol Cell Biochem. 2002;234-235 (1-2):119-24. (Pubitemid 34777848)
44. Jurcut R, Wildiers H, Ganame J, et al. Detection and monitoring of cardiotoxicity - what does modern cardiology offer? Support Care Cancer. 2008;16:437-45.
45. Rusconi P, Gomez-Marin O, Rossique-Gonzalez M, et al. Carvedilol in children with cardiomyopathy: 3-Year experience at a single institution. J Heart Lung Transplant. 2004;23:832-8. (Pubitemid 38953866)
46. Lowis S, Lewis I, Elsworth A, et al. A phase I study of intravenous liposomal daunorubicin (DaunoXome) in paediatric patients with relapsed or resistant solid tumours. Br J Cancer. 2006;95:571-80. (Pubitemid 44325896)
47. Lebrecht D, Kokkori A, Ketelsen UP, Setzer B, Walker UA. Tissue-specific mtDNA lesions and radical associated mitochondrial dysfunction in human hearts exposed to doxorubicin. J Pathol. 2005;207:436-44. (Pubitemid 43025692)
48. Ryberg M, Nielsen D, Cortese G, et al. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. J Natl Cancer Inst. 2008;100:1058-67.
49. Tokarska-Schlattner M, Zaugg M, Zuppinger C, Wallimann T, Schlattner U. New insights into doxorubicin induced cardiotoxicity: the critical role of cellular energetic. J Mol Cell Cardiol. 2006;41:389-405. (Pubitemid 44362995)
50. Chen B, Peng X, Pentassuglia L, Lim CC, Sawyer DB. Molecular and cellular mechanisms of anthracycline cardiotoxicity. Cardiovasc Toxicol. 2007;7:114-21. (Pubitemid 47339857)
51. Lipshultz SE, Scully RE, Smith HM. Serum cardiovascular growth factors during doxorubicin chemotherapy in children with leukemia." In: Proceedings of the 5th World Congress of Paediatric Cardiology and Cardiac Surgery (PCCS 09), Cairns, Australia, June 2009, Cardiomyopathy Poster Session. PCCS2009 Program page 133.
52. Tukenova M, Guibout C, Oberlin O, et al. Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J Clin Oncol. 2010;28:1308-15.
53. •• Landy DC, Miller TL, Lipsitz SR, et al. Cranial irradiation as an additional risk factor for anthracycline cardiotoxicity in childhood cancer survivors: an analysis from the Cardiac Risk Factors in Childhood Cancer Survivors Study. Pediatr Cardiol. 2013;34:826-34. This study describes the additional risk from cranial irradiation exposure in childhood cancer survivors. Survivors exposed to cranial irradiation had significantly greater decreases in LV mass and LV dimension compared with those unexposed. Exposed survivors were also more likely to have low insulin-like growth factor-1 relative to normal values than unexposed, an observation possibly mediated by growth hormone deficiency. These findings suggest that growth hormone replacement therapy may help prevent the development of cardiotoxicity.
54. •• Armstrong GT, Oeffinger KC, Chen Y, et al. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol. 2013;31:3673-80. This study evaluates modifiable cardiovascular risk factors, particularly hypertension, and their potentiation of therapy-associated risk for major cardiac events in childhood cancer survivors. These findings suggest that modifiable risk factors should be the focus of future interventional studies to minimize the risk of cardiac events in long-term childhood cancer survivors.
55. Oberfield SE, Sklar CA. Endocrine sequelae in survivors of childhood cancer. Adolesc Med. 2002;13:161-70.
56. Lipshultz SE, Vlach SA, Stuart R, et al. Cardiac changes associated with growth hormone therapy among children treated with anthracyclines. Pediatrics. 2005;115:1613-22. (Pubitemid 43843171)
57. •• Lipshultz SE, Landy DC, Lopez-Mitnik G, et al. Cardiovascular status of childhood cancer survivors exposed and unexposed to cardiotoxic therapy. J Clin Oncol. 2012;30:1050-7. This study demonstrates that childhood cancer survivors, regardless of whether they received cardiotoxic treatments or not, were at increased risk of cardiotoxicity. This observation highlights the importance of including cardiovascular concerns as part of general survivorship guidelines.
58. Braunwald E. Biomarkers in heart failure. N Engl J Med. 2008;358:2148-59.
59. Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 2004;109:2749-54. (Pubitemid 38737923)
60. •• Lipshultz SE, Miller TL, Scully RE, et al. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J Clin Oncol. 2012;30:1042-9. This study demonstrates that elevations in cardiac troponin T and NT-proBNP in the first 90 days of doxorubicin treatment are associated with abnormal left ventricular structure and function 4 years later in childhood cancer survivors. These findings suggest that these serum biomarkers may potentially be used as biomarkers of cardiotoxicity in this population; however more studies are needed to validate and fully establish their clinical utility.
61. Mavinkurve-Groothuis AM, Marcus KA, Pourier M, et al. Myocardial 2D strain echocardiography and cardiac biomarkers in children during and shortly after anthracycline therapy for acute lymphoblastic leukaemia (ALL): a prospective study. Eur Heart J Cardiovasc Imaging. 2013;14:562-9.
62. Sawaya H, Sebag IA, Plana JC, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging. 2012;5:596-603.
63. Ylanen K, Poutanen T, Savikurki-Heikkila P, et al. Cardiac magnetic resonance imaging in the evaluation of the late effects of anthracyclines among longterm survivors of childhood cancer. J Am Coll Cardiol. 2013;61:1539-47.
64. Toro-Salazar OH, Gillan E, O'Loughlin M, et al. Occult cardiotoxicity in childhood cancer survivors exposed to anthracycline therapy. Circ Cardiovasc Imaging. 2013;6:873-80.
65. Hochster HS. Clinical pharmacology of dexrazoxane. Semin Oncol. 1998;25:37-42. (Pubitemid 28460382)
66. Walker DM, Fisher BT, Seif AE, et al. Dexrazoxane use in pediatric patients with acute lymphoblastic or myeloid leukemia from 1999 and 2009: analysis of a national cohort of patients in the pediatric health information systems database. Pediatr Blood Cancer. 2013;60:616-20.
67. Kalam K, Marwick TH. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis. Eur J Cancer. 2013;49:2900-9.
68. Lipshultz SE, Rifai N, Dalton VM, et al. The effect of dexrazoxane on myocardial injury in doxorubicintreated children with acute lymphoblastic leukemia. N Engl J Med. 2004;351:145-53. (Pubitemid 38886649)
69. Vrooman LM, Neuberg DS, Stevenson KE, et al. The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium. Eur J Cancer. 2011;47:1373-9.
70. Tebbi CK, London WB, Friedman D, et al. Dexrazoxane associated risk for acute myeloid leukemia/ myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin Oncol. 2007;25:493-500. (Pubitemid 350002954)
71. Salzer WL, Devidas M, Carroll WL, Winick N, Pullen J, Hunger SP, et al. Long-term results of the pediatric oncology group studies for childhood acute lympho- blastic leukemia 1984-2001: a report from the children's oncology group. Leukemia. 2010;24:355-70.
72. •• Lipshultz SE, Scully RE, Lipsitz SR, et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicintreated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol. 2010;11:950-61. This study demonstrates the cardioprotective effect of dexrazoxane in childhood cancer survivors of high-risk ALL, particularly in girls, without interfering with oncologic efficacy. However, because its cardioprotection was insufficient in some groups, future studies should focus on better predictors of at-risk patients and additional preventive therapies.
73. Lipshultz SE, Lipsitz SR, Sallan SE, et al. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol. 2002;20:4517-22. (Pubitemid 35402954)
74. Silber JH, Cnaan A, Clark BJ, et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol. 2004;22:820-8. (Pubitemid 41103593)
75. Grenier MS, Lipshultz SE. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol. 1998;25:72-85. (Pubitemid 28460388)